|
Characteristic
|
Non-targeted therapy
|
Bev-combined therapy
|
Cet-combined therapy
|
|---|
|
Metastatic tumors
|
252 (66.3)
|
44 (11.6)
|
84 (22.1)
|
|
Primary tumor site
|
|
Right side
|
36 (14.3)
|
17 (38.6)
|
14 (16.7)
|
|
Left side
|
216 (85.7)
|
27 (61.4)
|
70 (83.3)
|
|
Primary tumor grade
|
|
G1–2
|
189 (75.0)
|
35 (79.5)
|
50 (59.5)
|
|
G3
|
63 (25.0)
|
9 (20.5)
|
34 (40.5)
|
|
Histological subtype of primary tumor
|
|
Non-mucinous
|
228 (90.5)
|
42 (95.5)
|
74 (88.1)
|
|
Mucinous
|
24 (9.5)
|
2 (4.5)
|
10 (11.9)
|
|
Primary tumor pT categorya
|
|
pT1–2
|
31 (12.3)
|
2 (4.5)
|
4 (4.8)
|
|
pT3–4
|
221 (87.7)
|
42 (95.5)
|
80 (95.2)
|
|
Primary tumor pN categorya
|
|
pN0
|
106 (42.1)
|
29 (65.9)
|
26 (31.0)
|
|
pN1–2
|
146 (57.9)
|
15 (34.1)
|
58 (69.0)
|
|
CEA declineb
|
|
Yes
|
136 (54.0)
|
35 (79.5)
|
55 (65.5)
|
|
No
|
56 (22.2)
|
7 (15.9)
|
6 (7.1)
|
|
Unevaluable
|
60 (23.8)
|
2 (4.5)
|
23 (27.4)
|
|
Metastases presentation
|
|
Synchronous
|
208 (82.5)
|
40 (90.9)
|
67 (79.8)
|
|
Metachronous
|
44 (17.5)
|
4 (9.1)
|
17 (20.2)
|
|
Size of metastases (cm)
|
|
< 2.5
|
154 (61.1)
|
15 (34.1)
|
58 (69.0)
|
|
≥ 2.5
|
98 (38.9)
|
29 (65.9)
|
26 (31.0)
|
|
Resection status of liver metastases
|
|
R0
|
171 (67.9)
|
36 (81.8)
|
48 (57.1)
|
|
R1–2
|
81 (32.1)
|
8 (18.2)
|
36 (42.9)
|
|
Duration of preoperative chemotherapyc
|
|
Short duration
|
109 (43.3)
|
23 (52.3)
|
31 (36.9)
|
|
Long duration
|
143 (56.7)
|
21 (47.7)
|
53 (63.1)
|
|
Chemotherapy backbone
|
|
Oxa-based
|
184 (73.0)
|
29 (65.9)
|
16 (19.0)
|
|
Iri-based
|
52 (20.6)
|
15 (34.1)
|
66 (78.6)
|
|
Oxa + Iri-based
|
13 (5.2)
|
0 (0.0)
|
2 (2.4)
|
|
Fluoropyrimidine only
|
3 (1.2)
|
0 (0.0)
|
0 (0.0)
|
|
TRGd
|
|
1–2
|
95 (37.7)
|
21 (47.7)
|
32 (38.1)
|
|
3
|
97 (38.5)
|
15 (34.1)
|
32 (38.1)
|
|
4–5
|
60 (23.8)
|
8 (18.2)
|
20 (23.8)
|
- All data are presented as number of metastases followed by percentages in parentheses
-
Bev bevacizumab, Cet cetuximab, CEA carcinoembryonic antigen, Oxa oxaliplatin, Iri irinotecan, TRG tumor regression grade
-
a According to the Union for International Cancer Control (UICC) staging system (7th edition)
-
b The CEA decline was based on the comparison between the preoperative CEA and the baseline CEA detection. Because initial CEA levels were unavailable, 30 of 159 patients (85 of 380 available tumors) were not evaluable for CEA variations
-
c Short duration of preoperative chemotherapy: ≤ 4 cycles for 2-week regimens or ≤ 3 cycles for 3-week regimens; long duration of preoperative chemotherapy: > 4 cycles for 2-week regimens or > 3 cycles for 3-week regimens
-
d TRG was evaluated as metastases-related analysis
